Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus combination chemotherapy vs chemotherapy alone in first-line metastatic or recurrent head and neck squamous cell carcinoma
2007-005722-79Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab in head and neck squamous cell carcinoma (HNSCC) and head and neck cancer (HNC) (2 arms), sponsored by Amgen. Primary endpoint: Progression-free survival (PFS) during first-line treatment. Started Apr 2008; status: completed.
02
Drugs
panitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)head and neck cancer (HNC)
Beyond the preview
Go deeper on 2007-005722-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005722-79.